

Invitation to investor meeting with Modus Therapeutics Holding AB

On March 9, John Öhd, CEO of Modus Therapeutics Holding AB, will participate in the Small Cap Invest investor meeting.

Modus Therapeutics is aiming for a paradigm shift in treatment for sepsis, one of the deadliest and most expensive medical conditions in the world. John Öhd provides a status update based on the recently published positive top-line data from the company's Phase 1b LPS challenge study evaluating the potential of sevuparin as a new treatment for sepsis. After the presentation of approximately 20 minutes, there is an opportunity to ask questions.

Date: Thursday March 9 at 14:00

Notification: <https://small-cap-invest.confetti.events/>

About Small Cap Invest

Dagens PS investor meeting, Small Cap Invest, is a free and digital investor meeting. Interesting cases are presented here that provide you with a safe basis for investing in the presenting companies. During the investor meeting, you are also given the opportunity to ask questions to the companies.

For more information on Modus Therapeutics, please contact:

John Öhd, CEO, Modus Therapeutics

Phone: +46 (0) 70 766 80 97

Email: john.ohd@modustx.com

About Modus Therapeutics and sevuparin

Modus Therapeutics is a Swedish biotechnology company headquartered in Stockholm that develops sevuparin with a focus on diseases with a high unmet medical need. The company's focus in the near future is to develop sevuparin for patients with sepsis / septic shock, which is a serious and often fatal condition. Modus Therapeutics is listed on the Nasdaq First North Growth market ("MODTX"). More information is available at www.modustx.com.

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.

Attachments

Invitation to investor meeting with Modus Therapeutics Holding AB